829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers

• Michael Curran,
• James Barlow,
• Manuela Iezzi,
• Laura Conti,
• Elisabetta Bolli,
• Federica Cavallo,
• Ahmad Salameh,
• Paul Blezinger,
• Christine Gagliardi,
• Federica Pericle,
• Chiara Cossu

Affiliations

Michael Curran

4The University of Texas MD Anderson Cancer Center, Houston, TX, USA

James Barlow

1ImmunoGenesis, Inc., Houston, TX, USA

Manuela Iezzi

3G. d’Annunzio University of Chieti-Pescara, Chieti-Pescara, Italy

Laura Conti

2University of Turin, Turin, Italy

Elisabetta Bolli

2University of Turin, Turin, Italy

Federica Cavallo

2University of Turin, Turin, Italy

Ahmad Salameh

1ImmunoGenesis, Inc., Houston, TX, USA

Paul Blezinger

1ImmunoGenesis, Inc., Houston, TX, USA

Christine Gagliardi

1ImmunoGenesis, Inc., Houston, TX, USA

Federica Pericle

1ImmunoGenesis, Inc., Houston, TX, USA

Chiara Cossu

2University of Turin, Turin, Italy